formoterol

Also found in: Medical.
(redirected from Formoterol fumarate)
Translations

formoterol

n formoterol m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive
Combination products available in South Africa * Combination Device Dose, [micro]g Fluticasone propionate/ DPI (Accuhaler) 100/50 salmeterol 250/50 500/50 Fluticasone propionate/ pMDI 50/25 salmeterol 125/25 250/25 Budesonide/formoterol pMDI 80/4.5 fumarate 160/4.5 Budesonide/formoterol DPI (Turbuhaler) 80/4.5 fumarate 160/4.5 320/9 Fluticasone furoate/ pMDI 100/25 vilanterol ([dagger]) Mometasone furoate/ pMDI 100/5 formoterol fumarate Mometasone furoate/ pMDI CFC free 100/5 formoterol fumarate 200/5 pMDI = pressurised metered-dose inhaler; DPI = dry powder inhaler; CFC = chlorofluorocarbon.
Aclidinium bromide (99.84%) and formoterol fumarate dihydrate (99.94) were kindly supplied by the National Organization for Drug Control and Research (NODCAR), Giza, Egypt.
The Food and Drug Administration has approved glycopyrrolate and formoterol fumarate inhalation aerosol for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), according to a statement from AstraZeneca.
One group received a combination product, budesonide (400 [micro]g) and formoterol fumarate (6 [micro]g) as a single inhaled dose, while the other group received budesonide (400 [micro]g) inhaled dose and montelukast (10 mg) as an oral dose.
The FP/FORM combination brings together the attributes of the two compounds: fluticasone propionate, the most widely prescribed inhaled corticosteroid in Europe*and formoterol fumarate, a long-acting beta2-agonist characterised by a fast onset of action.
The fixed-dose combination of mometasone furoate and formoterol fumarate was developed by Schering-Plough and inherited by Merck when it acquired its smaller rival last year.
The changes will result in ScheringPlough assuming exclusive worldwide rights to develop and commercialize a fixed-dose combination of its inhaled corticosteroid ASMANEX (mometasone furoate inhalation powder), and Novartis' long-acting beta2-adrenergic receptor agonist, FORADIL (formoterol fumarate).
Schering-Plough will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of its inhaled corticosteroid Asmanex (mometasone furoate inhalation powder), and Novartis' long-acting beta2-adrenergic receptor agonist, Foradil (formoterol fumarate).
- The US Food and Drug Administration has approved Duaklir Pressair (aclidinium bromide and formoterol fumarate) for the maintenance treatment of patients with chronic obstructive pulmonary disease, US-based Circassia Pharmaceuticals Inc said.
United States Food and Drug Administration (USFDA) has granted approval to UK-based Circassia Pharmaceuticals' DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) product for the treatment of chronic obstructive pulmonary disease, it was reported yesterday.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.